C
Christopher J. Nirschl
Researcher at Brigham and Women's Hospital
Publications - 30
Citations - 3260
Christopher J. Nirschl is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Immune system & Immunotherapy. The author has an hindex of 14, co-authored 21 publications receiving 2632 citations. Previous affiliations of Christopher J. Nirschl include Johns Hopkins University & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng Ryong Woo,Meghan E. Turnis,Monica V. Goldberg,Jaishree Bankoti,Mark J. Selby,Christopher J. Nirschl,Matthew L. Bettini,David M. Gravano,Peter Vogel,Chih Long Liu,Stephanie Tangsombatvisit,Joseph F. Grosso,George J. Netto,Matthew P. Smeltzer,Alcides Chaux,Paul J. Utz,Creg J. Workman,Drew M. Pardoll,Alan J. Korman,Charles G. Drake,Dario A. A. Vignali +20 more
TL;DR: A strong synergy between the PD-1 and LAG-3 inhibitory pathways in tolerance to both self and tumor antigens is defined and it is argued strongly that dual blockade of these molecules represents a promising combinatorial strategy for cancer.
Journal ArticleDOI
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Andrew B. Sharabi,Christopher J. Nirschl,Christina M. Kochel,Thomas R. Nirschl,Brian Francica,Esteban Velarde,Theodore L. DeWeese,Charles G. Drake +7 more
TL;DR: The ability of stereotactic XRT to induce endogenous antigen-specific immune responses when it is combined with anti–PD-1 checkpoint blockade immunotherapy is demonstrated and provides an additional mechanistic rationale for combining radiation with PD-1 blockade in the clinic.
Journal ArticleDOI
Oncogenic Kras Activates a Hematopoietic-to-Epithelial IL-17 Signaling Axis in Preinvasive Pancreatic Neoplasia
Florencia McAllister,Jennifer M. Bailey,Janivette Alsina,Christopher J. Nirschl,Rajni Sharma,Hongni Fan,Yanique Rattigan,Jeffrey C. Roeser,Rachana H. Lankapalli,Hao Zhang,Elizabeth M. Jaffee,Charles G. Drake,Franck Housseau,Anirban Maitra,Jay K. Kolls,Cynthia L. Sears,Drew M. Pardoll,Steven D. Leach +17 more
TL;DR: Together, these studies suggest that a hematopoietic-to-epithelial IL-17 signaling axis is a potent and requisite driver of PanIN formation.
Journal ArticleDOI
Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy
TL;DR: Current data regarding immune checkpoint molecule signaling and coexpression, both in cancer and infectious disease, as well as the results of preclinical and clinical manipulations of checkpoint proteins are reviewed.
Journal ArticleDOI
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Allison Martin,Thomas R. Nirschl,Christopher J. Nirschl,Brian Francica,Christina M. Kochel,A van Bokhoven,Alan K. Meeker,M S Lucia,Robert A. Anders,Angelo M. DeMarzo,Charles G. Drake +10 more
TL;DR: In human prostate cancer, PTEN loss is not associated with PD-L1 expression, arguing against innate immune resistance as a mechanism that mitigates antitumor immune responses in this disease.